Central administration of Dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1
Article in Biomedicine & Pharmacotherapy (November 2023)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Biomedicine & Pharmacotherapy (November 2023)
Article in Reviews in Endocrine and Metabolic Disorders (July 2023)
Article in Nutrition Research Reviews (June 2021)